BioSpace News Archive

Here’s a look at some of the biggest U.S. Nasdaq-based initial public offerings in 2019 and some of the more intriguing ones.

Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look.

Less than a month after snagging approval for a first-of-its-kind sickle cell disease treatment, Global Blood Therapeutics (GBT) is already looking at next-generation measures to tackle the disorder, as well as other diseases of the blood such as beta thalassemia.

The U.S. Government is increasing the measures it is taking to counter what it sees as a growing threat to scientific intellectual property from China.

Job interviewing can be an unnerving experience, but if you know how to handle some of the stickiest situations encountered in interviewing, you can be that much more confident.

Boston-based Stealth BioTherapeutics reported that its Phase III MMPOWER-3 clinical trial of elamipetride failed to meet its primary endpoint.

Moving into the holidays and the fast-approaching end of the year, the U.S. Food and Drug Administration (FDA) got busy wrapping up a number of to-do items. Here’s a look.

As part of strategic refocusing, AstraZeneca sold the rights to two cancer drugs in several countries in Europe, Africa and other countries to Juvisé Pharmaceuticals.

Looking back over the past year and even decade, STAT News takes a look back at the best drugs approved over the past 10 years in its weekly Readout podcast.

OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today announced the release of a detailed presentation highlighting the Company’s strategic rationale – and benefits for shareholders – of the proposed transaction with Grand Decade Developments Limited,